ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ONC Oncimmune Holdings Plc

21.20
0.20 (0.95%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Oncimmune Holdings Plc LSE:ONC London Ordinary Share GB00BYQ94H38 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.20 0.95% 21.20 20.60 22.00 21.00 21.00 21.00 12,949 16:35:29
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Medical Laboratories 1.47M -6.15M -0.0830 -2.53 15.57M

Oncimmune Holdings PLC Autoantibody profiling agreement signed (7416X)

02/09/2020 7:04am

UK Regulatory


Oncimmune (LSE:ONC)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Oncimmune Charts.

TIDMONC

RNS Number : 7416X

Oncimmune Holdings PLC

02 September 2020

2 September 2020

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Autoantibody profiling programme agreement signed with leading global biopharmaceutical company

Fourth ImmunoINSIGHTS partnership agreement signed with top ten biopharmaceutical company in under four months

Pilot programme to profile patients receiving checkpoint inhibitor ("CPI") therapy

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, today announces it has signed an autoantibody profiling collaboration with a leading global biopharmaceutical company with extensive experience in developing novel immune checkpoint inhibitors ("CPIs") (the "Agreement"). The programme, which is scheduled to complete in Q2 2021, will evaluate the autoantibody profiles from patient samples collected in a clinical trial of a CPI. Such profiling is expected to enable the biopharmaceutical partner to identify better the groups of patients likely to both tolerate a particular CPI treatment and also those whose disease is likely to respond positively to that treatment.

Under the Agreement, Oncimmune will be utilising its proprietary biomarker discovery engine, SeroTag (R) , to identify tumour associated antibody markers that are predictive of response and immune-related adverse events. SeroTag is a high-throughput, multiplex technology based on one of the largest in-house protein libraries, as well as a unique, ever-growing repository of disease data for indications including, autoimmune diseases and cancer. Oncimmune is helping to address a number of challenges faced by drug developers for the successful development and broader application of both cancer immunotherapies and treatments for autoimmune diseases.

This is the fourth partnership agreement signed with a top ten biopharmaceutical company in less than four months and further demonstrates the potential of Oncimmune's unique technology and immune expertise to assist in the development of new and safer oncology treatments. It also underlines the success and growing momentum of Oncimmune's partnering strategy for ImmunoINSIGHTS.

The aim of the pilot is to further validate the power of Oncimmune's ImmunoINSIGHTS offering, ahead of signing a significantly larger partnership agreement in profiling patients on a range of immuno-oncology clinical trials.

Adam M Hill, CEO of Oncimmune said: "We are pleased to announce this partnership between our ImmunoINSIGHTS business and another world-leading biopharmaceutical company. The momentum we are building with the world's largest companies in the pharmaceutical industry is a testament to the value that a collaboration with Oncimmune can bring to their development programmes. Through these recent agreements, we look forward to further demonstrating the potential of ImmunoINSIGHTS to have a tangible and complementary impact on immuno-oncology clinical trial outcomes."

For further information:

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, Victoria Ayton

+44 (0)20 3829 5000

N+1 Singer (Joint Broker)

Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer

+44 (0)20 7496 3000

WG Partners (Joint Broker)

David Wilson, Chris Lee

+44 (0)203 705 9321

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com

+44 (0)20 3727 1000

About Oncimmune

Our intimate understanding of the human immune system enables us to harness its sophisticated response to disease to detect cancer earlier and to support the development of better therapies.

The key to improving cancer survival is early detection and better selection for therapy. As a company, we are driven by our passion to improve cancer survival and give people extra time. Oncimmune's immunodiagnostic test, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis.

The unique combination of our core technology and understanding of the immune system, powers our ImmunoINSIGHTS service; a proprietary platform that enables life science organisations to optimise drug development and delivery, leading to more effective, targeted as well as safer treatments for patients.

Oncimmune was founded in 2002 and launched its platform diagnostic technology in 2009, followed by the launch of its first commercial tests, EarlyCDT Lung and EarlyCDT Liver. To date, over 200,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled trial for the early detection of lung cancer using biomarkers, the successful National Health Service (NHS) Early detection of Cancer of the Lung ("ECLS") trial of 12,208 high-risk smokers in Scotland. This trial demonstrated that EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

What is ImmunoINSIGHTS?

The ImmunoINSIGHTS service business leverages Oncimmune's technology platform and methodologies across multiple diseases, to offer life-science organisations actionable insights for therapies across the development and product lifecycle. Our core immune-profiling technology is underpinned by our library of over eight thousand immunogenic proteins, one of the largest of its kind. This helps identify trial participants and patients into clinically relevant subgroups, enabling development of targeted and more effective treatments.

What is SeroTag?

Oncimmune's proprietary biomarker discovery engine, which is leveraged in our ImmunoINSIGHTS services to discover and validate novel biomarkers can help stratify patients in multiple cancer indications and with different autoimmune diseases.

This high-throughput, multiplex technology is based on one of the largest, in-house protein libraries, as well as a unique, ever-growing repository of disease data for indications including, but not limited to, autoimmune diseases and cancer. As a result, SeroTag is helping to address and monitor a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and treatments for autoimmune diseases.

The platform is being applied to discover and validate biomarkers and develop precision diagnostic tools from minimally invasive liquid biopsies. SeroTag analyses autoantibodies-some of the most stable analytes-and is used most frequently for the identification of IgG isoforms, in addition to IgM and IgA, from just a few drops of serum.

The SeroTag platform acts as the primary discovery engine that feeds into the creation of Oncimmune's NavigAID disease-specific stratification panels-precision medicine tools which are enabling patient and disease stratification and support therapeutic development.

For more information, visit www.oncimmune.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGRLBMMTMTTMTBM

(END) Dow Jones Newswires

September 02, 2020 02:04 ET (06:04 GMT)

1 Year Oncimmune Chart

1 Year Oncimmune Chart

1 Month Oncimmune Chart

1 Month Oncimmune Chart

Your Recent History

Delayed Upgrade Clock